文献速递艾滋病与性传播感染

简化多替拉韦单药治疗在原发性HIV感染早期启动cART患者中的非劣效性随机对照试验

Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.
PubMed 文献 · Clin Infect Dis · 2019-01-01

EARLY-SIMPLIFIED是一项随机、开放标签、多中心非劣效性试验,纳入在原发HIV-1感染后180天内启动cART且HIV-1 RNA<50 copies/mL持续至少48周的患者,按2:1随机分配至多替拉韦50 mg每日一次单药治疗组或继续cART组。第48周符合方案人群分析显示,多替拉韦单药组67/67(100%)与cART组32/32(100%)均达到病毒学应答,差异0.00%(95%CI -100%至4.76%),在预设非劣效界值10%下证明非劣效。

要点

  • 原发HIV感染早期启动cART且病毒抑制≥48周者,多替拉韦单药非劣于继续cART。
  • 第48周两组病毒学应答率均为100%,差异0.00%(95%CI -100%至4.76%)。
  • 未来简化治疗研究应按HIV感染时间和首次cART启动时间分层。

核心结论

  • 在原发HIV-1感染期间启动cART且HIV-1 RNA<50 copies/mL至少48周的患者中,每日一次多替拉韦单药治疗第48周病毒学应答非劣于继续cART。

研究设计与样本

  • EARLY-SIMPLIFIED为随机、开放标签、多中心非劣效性试验,共随机101例患者,多替拉韦单药组68例,继续cART组33例。

主要发现

  • 第48周符合方案人群中,多替拉韦单药组67/67(100%)与cART组32/32(100%)达到HIV-1 RNA<50 copies/mL,差异0.00%(95%CI -100%至4.76%)。
  • 该结果在预设非劣效界值10%下证明多替拉韦单药非劣效。

关键数值与推荐

  • 主要疗效终点为第48周或之前HIV-1 RNA<50 copies/mL的患者比例,非劣效界值为10%。
  • 入组条件为原发HIV-1感染 documented后<180天启动cART,且HIV-1 RNA<50 copies/mL持续至少48周。
  • 多替拉韦单药剂量为50 mg每日一次。

临床怎么用

  • 对于原发HIV感染早期启动cART且已稳定病毒抑制至少48周的患者,可考虑简化至多替拉韦单药治疗,但需注意此为试点研究。
  • 临床决策时应结合感染时间和cART启动时间进行分层评估。

局限性

  • 本研究为试点研究,样本量较小(共101例)。
  • 研究为开放标签设计。
  • 结论需在更大规模研究中验证,未来研究应按HIV感染时间和cART启动时间分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who start combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection show a smaller HIV-1 latent reservoir, less immune activation, and less viral diversity compared to patients who start cART during chronic infection. We conducted a pilot study to determine whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir monotherapy. METHODS: EARLY-SIMPLIFIED is a randomized, open-label, noninferiority trial. Patients who started cART <180 days after a documented primary HIV-1 infection and had an HIV-1 RNA <50 copies/mL plasma for at least 48 weeks were randomized (2:1) to monotherapy with dolutegravir 50 mg once daily or to continuation of cART. The primary efficacy endpoint was the proportion of patients with <50 HIV-1 RNA copies/mL on or before week 48; noninferiority margin 10%. RESULTS: Of the 101 patients randomized, 68 were assigned to simplification to dolutegravir monotherapy and 33 to continuation of cART. At week 48 in the per-protocol population, 67/67 (100%) had virological response in the dolutegravir monotherapy group vs 32/32 (100%) in the cART group (difference, 0.00%; 95% confidence interval, -100%, 4.76%). This showed noninferiority of the dolutegravir monotherapy at the prespecified level. CONCLUSION: In this pilot study consisting of patients who initiated cART during primary HIV-1 infection and had <50 HIV-1 RNA copies/mL for at least 48 weeks, monotherapy with once-daily dolutegravir was noninferior to cART. Our results suggest that future simplification studies should use a stratification according to time of HIV infection and start of first cART. CLINICAL TRIALS REGISTRATION: NCT02551523.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Braun DL, Turk T, Tschumi F, et al. Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clin Infect Dis. 2019. PMID: 30601950. doi:10.1093/cid/ciy1131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。